Specifically, slow-growing CML LSCs have been found to resist treatment with tyrosine kinase inhibitors (TKIs), even when BCR::ABL1 kinase activity is fully inhibited26–28. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.